Articles By Cyndi Root

  1. NIH Resumes MERS, Flu Studies 12/26/2014

    The National Institutes of Health (NIH) has allowed studies for MERS (Middle East respiratory syndrome) and the flu top resume.

  2. FDA Approves Teva's QNASL For Pediatric Patients With Allergic Rhinitis 12/26/2014

    Teva Pharmaceutical has a new allergy treatment for children as young as four years old.

  3. CRO KCR Acquires Clinical Portfolio From Ukrainian CRO AXIS 12/22/2014

    KCR, a contract research organization (CRO), has acquired the clinical portfolio of AXIS Group, a Ukrainian CRO.

  4. Lightlake, Adapt Pharma Partner On Intranasal Naloxone Opioid Overdose Reversal Treatment 12/18/2014

    Lightlake Therapeutics and Adapt Pharma Operations have begun a partnership on Lightlake's intranasal naloxone opioid overdose reversal treatment.

  5. Boehringer Ingelheim Enrolls Patients In Dabigatran Trial For Stroke 12/17/2014

    Boehringer Ingelheim has enrolled its first patient in a Phase 3 study of dabigatran etexilate (brand name Pradaxa) to prevent recurrent Embolic Stroke of Undetermined Source (ESUS).

  6. US FDA, Taiwan FDA Approve TWi Biotechnology's Phase 2 Gout Trial 12/17/2014

    TWi Pharmaceuticals is approved to run a Phase 2 trial of AC-201, according to the Food and Drug Administration (FDA) and the Taiwan FDA.

  7. Lakewood-Amedex, Batu Biologics File Separate INDs With FD 12/17/2014

    Batu Biologics has filed for approval of a Phase 1/2 clinical trial for non-small cell lung cancer (NSCLC) while Lakewood-Amedex is planning to conduct a Phase 1/2a trial for diabetic foot infections.

  8. La Jolla, George Washington University Partner On Angiotensin II For Hypotension, Shock 12/16/2014

    La Jolla Pharmaceutical Company and George Washington University (GW) have partnered to develop La Jolla’s angiotensin II products.

  9. FDA Grants Orphan Status To Arca's Ebola Treatment, Insys' Gastric Cancer Treatment 12/16/2014

    The Food and Drug Administration (FDA) has granted Orphan Drug status to an Ebola treatment and a gastric cancer treatment.

  10. FDA Approves Mast's Study Of Vepoloxamer In Acute Decompensated Heart Failure 12/15/2014

    Mast Therapeutics announced its intentions to develop vepoloxamer (MST-188) in heart failure.